(Q33331275)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Gemcitabine-cisplatin: a schedule finding study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

G J Peters

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

C J van Moorsel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

A Catik

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

J B Vermorken

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

H M Pinedo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

C J van Groeningen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 December 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

1503-1510

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Preclinical characteristics of gemcitabine.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Structural aspects of platinum anticancer drug interactions with DNA

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Comparative adverse effect profiles of platinum drugs.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Stereoselective, strong inhibition of ribonucleotide reductase from E. coli by cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Phase I study of gemcitabine using a once every 2 weeks schedule

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Cisplatin in the treatment of solid tumors: effect of dose and schedule

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Chemotherapy in oesophageal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008339425708

7 January 2021

Identifiers

DOI

10.1023/A:1008339425708

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10643544%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference